Business Context and Reporting Period
Company: SeaStar Medical Holding Corp
Filing Type: Form 8-K (Current Report)
Date of Report: October 30, 2023
Reporting Period: Single event date (October 30, 2023)
This filing reports a significant regulatory milestone regarding the Company's pediatric Selective Cytopheretic Device (SCD).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This Form 8-K is a current report focused on a specific regulatory event and does not contain financial statements or performance metrics.
Material Changes
Regulatory Approval Status: On October 30, 2023, the Company received an "Approvable Letter" from the U.S. Food and Drug Administration (FDA).
Subject: The letter pertains to the Company's Humanitarian Device Exemption (HDE) application for its pediatric Selective Cytopheretic Device (SCD).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the FDA communication. No specific financial guidance, future outlook, or risk factors are explicitly detailed within the text of this 8-K summary.
Investor Verification Checklist
- Verify the specific conditions or requirements outlined in the FDA "Approvable Letter" to understand the path to final approval.
- Review the full text of the press release filed as Exhibit 99.1 for additional context on the pediatric SCD.
- Confirm the timeline for the Company to address any remaining FDA requirements to secure the final HDE approval.
- Check subsequent filings for updates on the commercialization strategy following this regulatory milestone.